Sustained Impairment of Lurasidone Clearance After Discontinuation of Posaconazole: Impact of Obesity, and Implications for Patient Safety

Journal of Clinical Psychopharmacology
David J GreenblattChristina R Chow

Abstract

The antipsychotic agent lurasidone (Latuda®) is metabolized by Cytochrome P450-3A (CYP3A) enzymes. Coadministration with strong CYP3A inhibitors (such as ketoconazole, posaconazole, and ritonavir) is contraindicated due to the risk of sedation and movement disorders from high levels of lurasidone. This study evaluated the time-course of recovery from the posaconazole drug interaction, and the effect of obesity on the recovery process. Healthy normal-weight volunteers (n = 11, mean body mass index, BMI, = 23.1 kg/m) and otherwise healthy obese subjects (n = 13, mean BMI = 49.3 kg/m) received single doses of lurasidone in the baseline control condition, again during coadministration of posaconazole, and at 4 additional time points during the 2 weeks after posaconazole discontinuation. With posaconazole coadministration, lurasidone area under the concentration curve (AUC) increased by an arithmetic mean factor of 6.2 in normals, and by 4.9 in obese subjects. Post-treatment washout of posaconazole was slow in normals (mean half-life 31 hours), and further prolonged in obese subjects (53 hours). Recovery of lurasidone AUC toward baseline was correspondingly slow, and was incomplete. AUC remained significantly elevated above baseline...Continue Reading

References

May 1, 1986·Clinical Pharmacokinetics·D R Abernethy, D J Greenblatt
Mar 1, 1982·Clinical Pharmacokinetics·D R Abernethy, D J Greenblatt
Mar 10, 2000·Clinical Pharmacokinetics·K VenkatakrishnanD J Greenblatt
Oct 6, 2000·Clinical Pharmacokinetics·G Cheymol
Sep 16, 2009·PloS One·Thomas L KellySteven B Heymsfield
Jan 14, 2010·Clinical Pharmacokinetics·Michael J HanleyDavid J Greenblatt
May 21, 2010·Clinical Pharmacokinetics·Yanjun LiHartmut Derendorf
Jun 3, 2011·Clinical Pharmacology and Therapeutics·R JainC G Sahajwalla
Dec 20, 2011·Expert Opinion on Drug Metabolism & Toxicology·Gopal KrishnaEdward O'Mara
Mar 28, 2012·Clinical Pharmacokinetics·Margreke J E BrillCatherijne A J Knibbe
May 9, 2012·Expert Opinion on Pharmacotherapy·Roger S McIntyreJeanette M Jerrell
Dec 25, 2012·CNS Drugs·Mark Sanford
Mar 20, 2013·Nutrition & Diabetes·M A Stults-KolehmainenR Sinha
Nov 5, 2013·Journal of Clinical Densitometry : the Official Journal of the International Society for Clinical Densitometry·Steven PetakJohn A Shepherd
May 16, 2014·Drug Metabolism and Drug Interactions·Yu-Yuan ChiuAntony Loebel
Oct 24, 2014·Annual Review of Pharmacology and Toxicology·Catherijne A J KnibbeMeindert Danhof
Nov 28, 2014·Current Drug Metabolism·Toshiro NiwaHiroshi Yamazaki
Feb 24, 2015·CNS Drugs·Mark Sanford, Sohita Dhillon
Apr 30, 2015·British Journal of Clinical Pharmacology·David J Greenblatt, Jerold S Harmatz
Aug 5, 2015·Journal of Clinical Pharmacology·David J Greenblatt
Jun 3, 2017·BioMed Research International·Michele FornaroAndrea de Bartolomeis
Oct 21, 2015·Pharmacy : Journal of Pharmacy, Education and Practice·Simon LeungJade Machin
Dec 8, 2017·Journal of Clinical Psychopharmacology·David J GreenblattRichard I Shader
Mar 30, 2018·Journal of Clinical Psychopharmacology·David J GreenblattChristina R Chow

❮ Previous
Next ❯

Citations

Jun 19, 2018·Journal of Clinical Psychopharmacology·Antonio E NardiUNKNOWN International Task Force on Benzodiazepines
Dec 26, 2017·Clinical Pharmacology in Drug Development·David J Greenblatt
Aug 29, 2020·Journal of Clinical Pharmacology·David J GreenblattRichard I Shader
May 22, 2020·Journal of Clinical Pharmacology·Brit Silja Rohr, Gerd Mikus
Apr 24, 2020·Drugs·Lu ChenRoger J M Brüggemann
Jan 16, 2021·British Journal of Clinical Pharmacology·Christopher D BrunoDavid J Greenblatt
Jun 30, 2021·Journal of Clinical Pharmacology·Daniel Gonzalez, Jaydeep Sinha
Aug 3, 2021·Journal of Clinical Pharmacology·Christopher D BrunoDavid J Greenblatt

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic-Induced Weight Gain

Antipsychotic-induced weight gain (aiwg) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. Here are the latest discoveries pertaining to AIWG.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here